公开(公告)号：US12076403B2

公开(公告)日：2024-09-03

申请号：US17993799

申请日：2022-11-23

Applicant: Bausch Health Ireland Limited

Inventor： Arturo Angel ,  Gordon Dow

IPC: A61K47/14 ,  A61K9/00 ,  A61K9/06 ,  A61K9/107 ,  A61K9/127 ,  A61K9/14 ,  A61K31/573 ,  A61K31/58 ,  A61P17/06

CPC classification number: A61K47/14 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/107 ,  A61K9/127 ,  A61K31/573 ,  A61K31/58 ,  A61P17/06

Abstract: Pharmaceutical compositions for topical application to skin are provided. In some embodiments, the pharmaceutical compositions comprise a corticosteroid and further comprise a liquid oil component comprising one or more dicarboxylic acid esters and/or monocarboxylic acid esters.

公开(公告)号：US20240285531A1

公开(公告)日：2024-08-29

申请号：US18429272

申请日：2024-01-31

Applicant: The Regents of the University of California

Inventor： Andre E. Nel ,  Jeffrey I. Zink ,  Huan Meng

IPC: A61K9/127 ,  A61K9/51 ,  A61K31/337 ,  A61K31/4709 ,  A61K31/7068 ,  A61K31/7105 ,  A61K31/713 ,  A61K45/06 ,  A61K47/02

CPC classification number: A61K9/127 ,  A61K9/5115 ,  A61K31/337 ,  A61K31/4709 ,  A61K31/7068 ,  A61K31/7105 ,  A61K31/713 ,  A61K45/06 ,  A61K47/02

Abstract: A submicron structure comprising a silica body defining a plurality of pores that are suitable to receive molecules therein, and having a surface, and a phospholipid bilayer coating the surface, wherein said submicron structure has a maximum dimension of less than one micron, and wherein the phospholipid bilayer stably seals the plurality of pores; and wherein the submicron structure is a member of a monodisperse population of submicron structures.

公开(公告)号：US12059499B2

公开(公告)日：2024-08-13

申请号：US17313334

申请日：2021-05-06

Applicant: PLUMB PHARMACEUTICALS, INC.

Inventor： Timothy D. Heath ,  Lisa Ann Krugner-Higby ,  Amy Lautenbach

IPC: A61K9/127 ,  A61K31/4706 ,  A61K31/485 ,  A61K31/65

CPC classification number: A61K9/1278 ,  A61K9/127 ,  A61K31/4706 ,  A61K31/485 ,  A61K31/65 ,  Y10S977/773 ,  Y10S977/906 ,  Y10S977/907

Abstract: Provided herein is technology relating to incorporation of drugs into liposomes and particularly, but not exclusively, to methods for incorporating drugs into liposomes using a weak base and related compositions.

公开(公告)号：US20240252522A1

公开(公告)日：2024-08-01

申请号：US17279556

申请日：2019-09-25

Applicant: Celator Pharmaceuticals, Inc.

Inventor： Ronald CHEUNG ,  Stefan FADERL ,  Qi WANG

IPC: A61K31/704 ,  A61K9/127 ,  A61K31/635 ,  A61K31/7068

CPC classification number: A61K31/704 ,  A61K9/127 ,  A61K31/635 ,  A61K31/7068

Abstract: The invention relates to compositions and methods for treating patients with hematological proliferative disorders who are ineligible for treatment with standard intensive chemotherapy, using low intensity treatment with CPX-351, a liposomal composition of daunorubicin and cytarabine.

公开(公告)号：US12048766B2

公开(公告)日：2024-07-30

申请号：US16967203

申请日：2019-02-07

Applicant: L.E.A.F. HOLDINGS GROUP LLC

Inventor： Clet Niyikiza ,  Victor Mandla Moyo

IPC: A61K9/127 ,  A61K31/4015 ,  A61K31/513 ,  A61K31/519 ,  A61K45/06 ,  A61K47/26 ,  A61K47/69 ,  A61K49/00 ,  A61P35/00

CPC classification number: A61K9/127 ,  A61K9/1271 ,  A61K9/1272 ,  A61K9/1277 ,  A61K31/4015 ,  A61K31/513 ,  A61K31/519 ,  A61K45/06 ,  A61K47/26 ,  A61K47/6913 ,  A61K49/0054 ,  A61P35/00

Abstract: The disclosure relates generally to gamma polyglutamated tetrahydrofolate compositions, including delivery vehicles such as liposomes containing the gamma polyglutamated tetrahydrofolate, and methods of making and using the gamma polyglutamated tetrahydrofolate compositions to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., inflammation and autoimmune diseases such as rheumatoid arthritis). The disclosed compositions also have uses in combination therapy with one or more therapeutic agents to enhance the effectiveness or to reduce the toxicities associated with the therapeutic agent(s).

公开(公告)号：US12042560B2

公开(公告)日：2024-07-23

申请号：US14061426

申请日：2013-10-23

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Hiroshi Kikuchi ,  Kenji Hyodo ,  Hiroshi Ishihara

IPC: A61K9/127 ,  A61K31/357

CPC classification number: A61K9/127 ,  A61K9/1271 ,  A61K9/1277 ,  A61K9/1278 ,  A61K31/357

Abstract: The present invention provides a novel liposome composition containing eribulin or its pharmacologically permissible salt, and its method of manufacture.

公开(公告)号：US20240238200A1

公开(公告)日：2024-07-18

申请号：US18431490

申请日：2024-02-02

Applicant: DDS RESEARCH INC.

Inventor： Marianna FOLDVARI

IPC: A61K9/127 ,  A61K8/14 ,  A61K9/00 ,  A61K47/10 ,  A61K47/14 ,  A61K47/18 ,  A61K47/22 ,  A61K47/24 ,  A61P17/00 ,  A61Q19/08

CPC classification number: A61K9/127 ,  A61K8/14 ,  A61K9/0014 ,  A61K9/1273 ,  A61K47/10 ,  A61K47/14 ,  A61K47/186 ,  A61K47/22 ,  A61K47/24 ,  A61P17/00 ,  A61Q19/08

Abstract: The present application is related to a pharmaceutical composition a biphasic lipid vesicle comprising a lipid bilayer comprising vesicle forming lipids; an oil-in-water emulsion stabilized by one or more surfactants; one or more compounds; and one or more penetration enhancing agents. The one or more penetration enhancing agents include one or more non-ionic surfactants having a hydrophilic-lipophilic balance (HLB) of about 10 or less, alone or combination with one or more penetration enhancing agents selected from one or more of terpenes, alkaloids, salicylate derivatives, and polycationic surfactants and combinations thereof. The present application is also related to a pharmaceutical composition comprising a biphasic lipid vesicle comprising a lipid bilayer comprising vesicle forming lipids; an oil-in-water emulsion stabilized by one or more polycationic surfactants; and one or more compounds.

公开(公告)号：US12036232B2

公开(公告)日：2024-07-16

申请号：US17567482

申请日：2022-01-03

Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH

Inventor： Atta Behfar ,  Andre Terzic

IPC: C07H21/02 ,  A61K9/00 ,  A61K9/06 ,  A61K9/127 ,  A61K9/48 ,  A61K9/51 ,  A61K31/7105 ,  A61K47/36 ,  A61K48/00 ,  C07H21/04 ,  C12N15/113

CPC classification number: A61K31/7105 ,  A61K9/0019 ,  A61K9/06 ,  A61K9/127 ,  A61K9/48 ,  A61K9/5161 ,  A61K47/36 ,  A61K48/00 ,  C07H21/04 ,  C12N15/113

Abstract: A composition for delivering a biologic to a subject generally includes a particulate substrate and an mRNA encapsulated by the particulate substrate. In some cases, the mRNA may be indirectly attached to the particulate substrate. The mRNA encodes at least one therapeutic polypeptide. The composition may be delivered to a tissue of a subject to provide a therapeutic benefit to the tissue.

公开(公告)号：US20240228580A1

公开(公告)日：2024-07-11

申请号：US18405778

申请日：2024-01-05

Applicant: University of Kentucky Research Foundation

Inventor： Jill M. Kolesar ,  Christopher I. Richards

IPC: C07K14/74 ,  A61K9/127 ,  A61K35/15 ,  C12N5/0783 ,  C12N5/0784

CPC classification number: C07K14/70539 ,  A61K9/127 ,  A61K35/15 ,  C12N5/0636 ,  C12N5/0639

Abstract: An antigen-presenting dendritic cell membrane derived nanovesicle (CDNV) can be made by incubating a dendritic cell (DC) with an antigen and an agent to activate the DC, thereby generating a mature DC displaying a major histocompatibility complex class I (MHC) presenting the antigen, and fragmenting the membrane of the mature DC and allowing the fragmented membrane to assemble into a CDNV displaying the MHC presenting the antigen. The CDNV can be delivered to an environment including a T cell, thereby directly activating the T cell, or indirectly activating the T cell through a bystander antigen presenting cell (APC) that uptakes the CDNV and presents the antigen. The activated T cell and produce a T cell response.

公开(公告)号：US12029814B1

公开(公告)日：2024-07-09

申请号：US18488942

申请日：2023-10-17

Applicant: Subhash Dhawan ,  Yashi Dhawan

Inventor： Subhash Dhawan ,  Yashi Dhawan

IPC: A61K9/00 ,  A61K9/127 ,  A61K31/409 ,  A61K31/675 ,  A61N1/36 ,  A61P31/14

CPC classification number: A61K9/0046 ,  A61K9/127 ,  A61K31/409 ,  A61K31/675 ,  A61N1/36036 ,  A61P31/14

Abstract: Compound formulations and methods for preventing or treating upper respiratory virus infections, such as influenza, respiratory syncytia virus (RSV), SARS, and SARS-COV-2, in human and animal species are disclosed. The compounds may exhibit antiviral, antimicrobial, anti-inflammatory, or cytoprotective activities. Liquid formulations comprising one or more compounds may be administered into the outer canal of the ear for delivery to the nasal and oral cavities, nasopharynx, posterior pharynx and laryngopharynx, the primary sites of upper respiratory infections, located across the tympanic membrane (or eardrum) and eustachian tube, of the individuals infected with one or more upper respiratory viruses or other pathogens. Methods to facilitate trans-tympanic membrane translocation of the compounds by thermal, electrical or electromagnetic impulse, manual or mechanical muscle contraction or stimulation of muscles, nerves or tissues proximate to the eardrum are disclosed.